Chemours stock falls after Truist maintains buy rating despite guidance cut

Published 18/06/2025, 18:14
Chemours stock falls after Truist maintains buy rating despite guidance cut

Chemours (NYSE:CC) stock fell Tuesday after the chemical company lowered its second-quarter earnings guidance due to operational disruptions at its U.S. titanium dioxide facilities. The stock, currently trading at $11.37, has declined over 9.5% in the past week and 36.6% over the last six months, according to InvestingPro data.

The company now expects adjusted EBITDA of $215 million to $225 million for the quarter, below Wall Street’s consensus estimate of $236 million. This guidance reduction follows a challenging period where eight analysts have revised their earnings estimates downward, as tracked by InvestingPro. Chemours cited a rail line service interruption that impacted feedstock procurement at its Titanium Technologies business as a primary factor for the reduced outlook.

Despite the guidance cut, Truist Securities maintained its buy rating and $20.00 price target on Chemours. The firm noted that the company increased EBITDA guidance for its other two segments, with particularly strong performance in the Thermal & Specialized Solutions (TSS) division driven by higher-than-anticipated demand for Opteon products.

Chemours kept its Titanium Technologies sales guidance unchanged, which Truist viewed as a better indicator of market conditions than the adjusted EBITDA forecast. The firm also highlighted improved profitability in the Advanced Performance Materials (APM) segment as a positive development.

The operational challenges in the titanium dioxide business appear temporary, while the strength in other segments represents more durable positive trends, according to Truist’s analysis of the guidance update. InvestingPro analysis indicates the company is currently undervalued, despite operating with a significant debt burden and volatile stock performance. Subscribers can access 10+ additional ProTips and a comprehensive Pro Research Report for deeper insights into Chemours’ financial health and growth prospects.

In other recent news, The Chemours Company has revised its second-quarter 2025 outlook, driven by stronger-than-anticipated demand in its refrigerant business and improved cost performance in its advanced materials segment. The company expects consolidated net sales to rise by mid-teens sequentially, reaching the high end of its original forecast range. Chemours projects consolidated adjusted EBITDA to be between $215 million and $225 million, with positive free cash flow anticipated for the quarter. The Thermal & Specialized Solutions segment foresees approximately 25% sequential growth in net sales, fueled by demand for Opteon refrigerants due to U.S. regulations on low global warming potential options. However, the Titanium Technologies segment faces a projected 15% sequential decline in adjusted EBITDA due to operational disruptions, including a costly rail line service interruption. Additionally, Chemours has appointed Matthew Conti as Chief Human Resources Officer and Nathan Blom as Vice President for its liquid cooling portfolio, reflecting strategic moves to bolster human resources and expand in the liquid cooling market. The company has also entered into a partnership with DataVolt to enhance data center efficiency using innovative liquid cooling technologies. This collaboration aims to reduce environmental impact while improving performance, aligning with Chemours’ commitment to sustainable innovation.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.